Using joint tissue to guide treatment for pigmented villonodular synovitis
Part of Bones, joints & muscles, Cancer clinical trials.
This study looks at a special type of joint tissue to help doctors choose the best treatment for pigmented villonodular synovitis (PVNS), a condition where the lining of the joint grows too much and causes pain and swelling. By studying this tissue, doctors hope to improve care for patients with PVNS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with pigmented villonodular synovitis (PVNS), which may be in one spot or spread out in the joint
- You are being referred to a specialist to decide on treatment
- You are covered by a health insurance plan or social security
- You are not pregnant or nursing
- You do not have severe bleeding problems (like very low platelet count or are on strong blood thinners)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how chronic inflammatory illnesses progress over time and how treatments affect symptoms and disease markers. You may be invited if you’re receiving care for certain bowel, joint, or skin inflammatory conditions at the hospital.
This trial studies knee tissue to find better ways to diagnose early osteoarthritis. It may help people who need a knee injection for pain relief.
This study collects fluid from your joints (synovial fluid) or tissue from joint replacement surgery to look for biomarkers (biological clues) that could help doctors better diagnose bone and joint diseases.
This study examines joint tissue from people with different types of arthritis to understand the disease better. It may help researchers develop better treatments in the future.
This study looks at how inflammatory “cytokines” are expressed in people with psoriasis—both those with joint involvement and those without. It may help researchers understand what drives joint disease and guide better future monitoring or treatments.
This study looks at how a body signal called IL-23 may drive inflammation in spondyloarthritis (including joints) using samples from your care. It may help researchers identify which body cells and targets are involved, and how treatments could work better for active disease.
Hear when a new Synovitis Villonodular trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.